Dr Charles Cox obtained a BSc (Hons) in Genetics from Edinburgh University, prior to obtaining his PhD in Molecular Pathology from London University.Charles went on to complete a post-doctoral position at the Department of Medicine, Cambridge University, before taking on a senior post-doctoral position within the Cancer Genome Project, headed by Sir Mike Stratton, at the Wellcome Trust Sanger Institute. He played a key role in setting up and designing the platforms and infrastructure of this world leading effort into the identification of somatic mutations in cancer, and was a first author on the BRAF V600E paper.In 2004, Charles joined GlaxoSmithKline as Head of Genotyping within the Genetics department. Focussing on Pharmacogenetics, he oversaw genotyping activities of DNA from patients in GSK sponsored clinical trials, using genetic information to support the drug development process. Actively involved in the PREDICT-1 study, used to demonstrate prospectively the clinical utility of the HLA-B*57:01 marker in predicting HSR in patients receiving Abacavir, he continues to support GSK assets by using genetic biomarkers to help predict efficacy and better understand adverse events, in his current role as Head of Pharmacogenetics

Appearances:

﻿

Precision 2018 Day 2 @ 15:10

The evolution of Pharmacogenetics (PGx) as a tool to support drug development

What have we learned about PGx over the last 10 years

How best can we utilise this to support drug development going forward

Charles Cox / The evolution of Pharmacogenetics (PGx) as a tool to support drug development

Dr Charles Cox obtained a BSc (Hons) in Genetics from Edinburgh University, prior to obtaining his PhD in Molecular Pathology from London University.Charles went on to complete a post-doctoral position at the Department of Medicine, Cambridge University, before taking on a senior post-doctoral...